Assessment of aprotinin influence on periodontal  clinical status and matrix metalloproteinases 1, 2  and their tissue inhibitors saliva concentrations  in patients with chronic periodontitis.
OBJECTIVE
Assessment of the effect of treatment with aprotinin-containing drug on the clinical status of the periodontal tissue and on the concentrations of metalloproteinases released in the course of periodontitis (MMP-1, MMP-2) as well as their tissue inhibitors (TIMP-1 and TIMP-2) in the saliva of patients with chronic periodontitis (CP).


METHODS
The study involved 25 subjects with CP (39-68 years), including 16 women and 9 men. The patients were prescribed aprotinin preparation to be taken for 2 weeks. The control group (C) involved 14 healthy subjects (41-65 years), including 10 women and 4 men. Two periodontal indices were assessed: the approximal plaque index (API) and bleeding on probing index (BOP). Periodontal pocket depth and clinical attachment level were also evaluated. The concentrations of MMP-1 and MMP-2 as well as TIMP-1 and TIMP-2 were determined by the ELISA method.


RESULTS
The mean salivary MMP-1 concentration in patients with CP was significantly higher before and after treatment, as compared to healthy subjects. The mean salivary MMP-2 concentration in CP patients at baseline was also higher as compared to the C group and increased after treatment. The mean salivary TIMP-1 and TIMP-2 concentration in CP patients was higher as compared to C group and increased after treatment.


CONCLUSIONS
Since the mean MMPs levels were found to be growing it can be assumed that aprotinin has no significant effect on the regulation of MMPs in the saliva of CP patients. It thus seems that aprotinin application after scaling has no additional therapeutic effect.
Pietruska
M
M
Department of Periodontal and Oral Mucosal Diseases, Medical University of Bialystok, Bialystok, Poland. perio@umwb.edu.pl
Pietruski
J
J
Skurska
A
A
Bernaczyk
A
A
Zak
J
J
Zelazowska
B
B
Dolińska
E
E
Paniczko-Drezek
A
A
Wysocka
J
J
D000328:Adult; D000368:Aged; D007611:Aprotinin / Q000627:therapeutic use*; D055113:Chronic Periodontitis / Q000188:drug therapy* / Q000201:enzymology; D003774:Dental Plaque Index; D012534:Dental Scaling; D005260:Female; D005884:Gingival Hemorrhage / Q000188:drug therapy / Q000201:enzymology; D006801:Humans; D008297:Male; D020781:Matrix Metalloproteinase 1 / Q000032:analysis*; D020778:Matrix Metalloproteinase 2 / Q000032:analysis*; D008875:Middle Aged; D017622:Periodontal Attachment Loss / Q000188:drug therapy / Q000201:enzymology; D010512:Periodontal Index; D010514:Periodontal Pocket / Q000188:drug therapy / Q000201:enzymology; D010519:Periodontium / Q000187:drug effects / Q000201:enzymology; D016745:Root Planing; D012463:Saliva / Q000187:drug effects / Q000201:enzymology*; D015842:Serine Proteinase Inhibitors / Q000627:therapeutic use*; D019715:Tissue Inhibitor of Metalloproteinase-1 / Q000032:analysis*; D019716:Tissue Inhibitor of Metalloproteinase-2 / Q000032:analysis*
D015842:Serine Proteinase Inhibitors; D019715:Tissue Inhibitor of Metalloproteinase-1; D019716:Tissue Inhibitor of Metalloproteinase-2; D007611:Aprotinin; C522361:MMP2 protein, human; D020778:Matrix Metalloproteinase 2; C522360:MMP1 protein, human; D020781:Matrix Metalloproteinase 1